Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | 1.855% | 1.855% | -41.388% | -84.173% |
| iShares Core DAX® | 2.821% | -1.953% | 15.071% | 11.862% |
| iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% | 40.075% |
| iShares Nikkei 225® | 3.687% | -4.221% | 14.286% | 6.629% |
| iShares S&P 500 | 3.577% | -2.240% | 25.546% | 38.398% |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc